BioCardia to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

March 15, 2021

SAN CARLOS, Calif. – BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

Investors can view Dr. Altman’s live fireside chat presentation at 3:30pm ET on March 19 and once registered for the conference here, can listen to a corporate presentation which will be available on the conference website.  Investors can also request a 1x1 meeting with Dr. Altman to be arranged following the conclusion of the conference.

About BioCardia®

BioCardia, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development.  The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio.  BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.  For more information, visit

David McClung, Chief Financial Officer
(650) 226-0120

Michelle McAdam, Chronic Communications, Inc.
(310) 545-6654


Have questions?
: (800) 624-1179
Have questions?

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.